Jack A. Khattar - 18 Feb 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Reporting relationship
President, CEO, Director
Issuer ticker
SUPN
Reported as of
18 Feb 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
20 Feb 2026, 16:46:10 UTC
Prior SEC filing
10 Oct 2025
Next SEC filing
03 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Timothy C. Dec, as attorney-in-fact

Key filing fact

Jack A. Khattar filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 20 Feb 2026.

Key facts

  • This page summarizes Jack A. Khattar's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 20 Feb 2026, 16:46.

Change

  • Previous filing in this sequence was filed on 10 Oct 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001539937 Primary reporting owner

Khattar Jack A.

Relationship
President, CEO, Director
Address
C/O SUPERNUS PHARMACEUTICALS INC., 9715 KEY WEST AVENUE, ROCKVILLE
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Signature date
20 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SUPN transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+341,610
Change %
Price
$0.000000
Shares after
341,610
Date
18 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
341,610
Exercise price
$50.20
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests in four equal annual installments beginning on February 18, 2027.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .